The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 180, 3569-3577
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soares, A. P.
Right arrow Articles by Hanekom, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soares, A. P.
Right arrow Articles by Hanekom, W. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Bacillus Calmette-Guérin Vaccination of Human Newborns Induces T Cells with Complex Cytokine and Phenotypic Profiles1

Andreia P. Soares*, Thomas J. Scriba*, Sarah Joseph*, Ryhor Harbacheuski{dagger}, Rose Ann Murray{dagger}, Sebastian J. Gelderbloem*, Anthony Hawkridge*, Gregory D. Hussey*, Holden Maecker{ddagger}, Gilla Kaplan{dagger} and Willem A. Hanekom2,*

* South African TB/Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, Vaccine Initiative, University of Cape Town, Cape Town, South Africa; {dagger} Laboratory of Mycobacterial Immunity and Pathogenesis, Public Health Research Institute, Newark, NJ 07103; and {ddagger} BD Biosciences, San Jose, CA 95131


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The immune response to vaccination with bacillus Calmette-Guérin (BCG), the only tuberculosis vaccine available, has not been fully characterized. We used multiparameter flow cytometry to examine specific T cell cytokine production and phenotypic profiles in blood from 10-wk-old infants routinely vaccinated with BCG at birth. Ex vivo stimulation of whole blood with BCG for 12 h induced expression of predominantly IFN-{gamma}, IL-2, and TNF-{alpha} in CD4+ T cells in seven distinct cytokine combinations. IL-4 and IL-10 expression was detected in CD4+ T cells at low frequencies and only in cells that did not coexpress type 1 cytokines. Specific CD8+ T cells were less frequent than CD4+ T cells and produced mainly IFN-{gamma} and/or IL-2 and less TNF-{alpha}, IL-4, and IL-10. Importantly, many mycobacteria-specific CD4+ and CD8+ T cells did not produce IFN-{gamma}. The predominant phenotype of BCG-specific type 1 T cells was that of effector cells, i.e., CD45RA–CCR7–CD27+, which may reflect persistence of Mycobacterium bovis BCG in infants until 10 wk of age. Among five phenotypic patterns of CD4+ T cells, central memory cells were more likely to be IL-2+ and effector cells were more likely to be IFN-{gamma}+. We concluded that neonatal vaccination with BCG induces T cells with a complex pattern of cytokine expression and phenotypes. Measuring IFN-{gamma} production alone underestimates the magnitude and complexity of the host cytokine response to BCG vaccination and may not be an optimal readout in studies of BCG and novel tuberculosis vaccination.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Nearly one-third of the global population is latently infected with Mycobacterium tuberculosis and ~2 million people die of tuberculosis (TB)3 disease every year (Tuberculosis Fact Sheet, 2005, World Health Organization, Geneva, Switzerland). Bacillus Calmette-Guérin (BCG), the only vaccine against TB currently available, has variable efficacy in preventing pulmonary disease (1), but 80% efficacy in preventing childhood miliary disease and meningitis (2). Our knowledge of immunity induced by BCG vaccination is incomplete, particularly after human newborn vaccination. However, infants will be targets of novel, safer, and more efficacious TB vaccines in the future and a better understanding of the immune response induced by newborn BCG vaccination is likely to facilitate development of improved vaccines.

Experimental evidence suggests that both CD4+ and CD8+ T cells are important for protection against mycobacteria (3, 4, 5, 6). In humans, the role of CD4+ T cells has been highlighted by a increased risk of disease after infection with M. tuberculosis when CD4+ T cell numbers decline in HIV-infected persons (7). A primary function of both CD4+ and CD8+ T cells is to produce the type 1 cytokine IFN-{gamma}. The critical role of this cytokine has been demonstrated by characteristic severe mycobacterial disease in patients with mutations of the IFN-{gamma} receptor (8, 9). Other type 1 cytokines, such as TNF-{alpha} and IL-2, may also be important in protection against TB: the role of TNF-{alpha} has been underscored by high rates of reactivation of latent TB following treatment of rheumatoid arthritis patients with specific inhibitors of this cytokine (10, 11); T cell IL-2 expression has been associated with long-term memory (12, 13), which is the aim of protective immunity. BCG vaccination of human newborns does indeed induce specific CD4+ and CD8+ T cells capable of producing IFN-{gamma} (14, 15, 16) Previous studies have also shown that BCG vaccination of infants induces TNF-{alpha}, which is detectable in plasma by ELISA (17). However, the pattern of production of all type 1 cytokines, on a single cell basis, has not been delineated.

Our aim was to also describe expression of type 2 cytokines such as IL-4, thought to reflect a suboptimal immune response to mycobacteria (18, 19). Although BCG vaccination of infants has been shown to induce low levels of type 2 cytokines (15, 16, 20), the detection was in plasma, and cell-associated expression has not been reported. We also wished to assess T cell IL-10 expression, since this cytokine is likely to be an important regulator of effector T cell responses against TB (21) and is induced by newborn BCG vaccination (15, 16, 22).

The memory phenotype of T cells induced by BCG vaccination of newborns has not been described. Ag-experienced cells may be categorized based on expression of surface markers (13, 23, 24, 25, 26). Central memory cells express CCR7 but not CD45RA and are likely to represent a long-lived population, which expands rapidly in lymph nodes following subsequent Ag encounter (23, 27). In contrast, effector cells are both CCR7– and CD45RA– and act immediately following Ag exposure, but have limited proliferative capacity (13, 23). A third subset, terminally differentiated memory cells are CD45RA+ and CCR7– and the most differentiated subpopulation, based on short telomere length and function (26, 28). Naive or non-Ag-experienced T cells characteristically express both CD45RA and CCR7 (13, 26, 28). Combination of markers other than CCR7 and CD45RA may also differentiate subsets of Ag-experienced cells. Fritsch et al. (26) recently proposed the phenotypic classification of CD4+ T cell populations based on expression of CD27 and CCR7. Central memory T cells were defined as CD27+ and CCR7+, effectors as CD27+ and CCR7–, and terminally differentiated T cells as CD27– and CCR7–. Our aim was to evaluate expression of all of these markers among Ag-experienced T cells induced by BCG. Although several investigators have characterized mycobacteria-specific immune responses by four-color flow cytometry (29, 30, 31), these studies could only measure two cytokines or phenotypic markers at a time and thus most likely underestimated the complexity of the response.

Our hypothesis was that BCG vaccination of newborns would induce both CD4+ and CD8+ T cells capable of producing multiple cytokines and that a central memory phenotype of specific cells would be dominant 10 wk after vaccination. We used an intracellular cytokine assay with multiparameter flow cytometry to comprehensively characterize these variables. To achieve our goals, we established clinical structures and optimized techniques (32) to overcome hurdles common to investigation of immunity in infants.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Study participants and blood collection

Healthy 10-wk-old infants, routinely vaccinated intradermally with BCG (Statens Serum Institut, Copenhagen, Denmark) at birth, were enrolled in the Cape Town region of South Africa. This area has a very high TB disease incidence in children 5-year old and younger, exceeding 2% per year in certain areas (32). Infants born to HIV-positive mothers, infants known to be HIV positive, infants with suspected or confirmed TB disease, infants with possible exposure to TB disease and infants with any other active or chronic illnesses at the time of enrollment were excluded. Human participation was according to the U.S. Department of Health and Human Services and good clinical practice guidelines. This included protocol approval by the University of Cape Town Research Ethics Committee and written informed consent. Sodium heparinized blood was collected from each infant. Two different cohorts were enrolled to preserve blood volume collected for assessment with two different flow cytometric protocols (see below): 29 infants to assess cytokine expression of T cells and 27 infants to assess the phenotype of IFN-{gamma}- and IL-2-expressing T cells.

Ags and Abs

BCG was reconstituted from the vaccine vial (SSI) at 1.8 x 106 organisms/ml as previously described (32). The positive control streptococcal enterotoxin B (SEB; Sigma-Aldrich) was used at 10 µg/ml. The costimulatory Abs anti-CD28 and anti-CD49d (both from BD Biosciences) were each used at 1 µg/ml. Cytokine profiles of BCG-specific T cells were examined using the following conjugated Abs: anti-CD3 Amcyan (SK7) and anti-IL-2 Alexa 610-PE (5344.111), both custom-conjugated at BD Biosciences; and anti-CD4 Alexa Fluor 700 (RPAT4), anti-CD8 Cy5.5-PerCP (SK1), anti-IL-4 FITC (MP4-25D2), anti-IFN-{gamma} PE (25723.11), anti-IL-10 allophycocyanin (JES3-19F1), and anti-TNF-{alpha} Cy7-PE (MAb11), all obtained from BD Biosciences. A separate protocol was used for assessing T cell phenotypes using the following conjugated Abs: anti-CD3 PacBlu (UCHT1), anti-CD4 Cy5.5PerCP (SK3), anti-CD8 Cy5.5PerCP (SK1), anti-CD45RA Cy7PE (L48), anti-CD27 PE (MT271), anti-IFN-{gamma} AlexaFluor 700 (B27) and anti-IL-2 FITC (5344.111), all obtained from BD Biosciences, and anti-CCR7 allophycocyanin (150503), obtained from R&D Systems.

Whole blood intracellular cytokine detection assay

To determine cell-associated cytokine production, 1 ml of heparinized whole blood was incubated with BCG and anti-CD28 and anti-CD49d as described before (32). Blood incubated with SEB and costimulants, or with costimulatory Abs alone (UNS), served as positive and negative controls, respectively. Brefeldin A (10 µg/ml; Sigma-Aldrich) was added during the last 5 h of incubation to capture cytokines intracellularly. After a total incubation of 12 h, RBC were lysed and white blood cells were fixed with FACS Lysing Solution (BD Biosciences), followed by cryopreservation.

Cell staining and flow cytometric analysis

To detect intracellular cytokines, cryopreserved cells were thawed, washed in PBS, permeabilized with Perm/Wash solution (BD Biosciences), and incubated at 4°C with fluorescence-conjugated Abs for 1 h. To assess T cell memory phenotypes, a two-step staining method, resulting in optimal staining, was used: cells were thawed, washed in PBS, and permeabilized with Perm/Wash solution and then incubated with surface marker Abs for 1 h at 4°C, followed by an additional hour with Abs specific for intracellular cytokines. Flow cytometric acquisition was completed on a LSRII flow cytometer (BD Biosciences) configured for 3 lasers and 12 detectors. All of the cells in the tube were acquired. Analysis was performed using FACSDiva software (BD Biosciences). Although automated compensation with mouse IgG {kappa} beads was applied, compensation settings were assessed manually after acquisition and adjusted if necessary. Multiparameter panel development (data not shown) included evaluation of appropriate staining controls of Ab and fluorochrome interactions and of spectral overlap using control blood samples (33, 34).

Cutoffs to determine positive cytokine expression in CD4+ and CD8+ T cells from blood incubated with BCG were set using cells from blood incubated with costimulatory Abs alone (negative control) (Fig. 1A). Angled cutoff lines were necessary for some fluorochromes, because of data spread at higher fluorescence intensities, following instrument compensation (e.g., Fig. 1). SEB was an excellent positive control for induction of all cytokines, except IL-4. IL-4-expressing HICK-2 cells (BD Biosciences), processed per the manufacturer’s protocol, were used as positive control for IL-4. Where distinction between positive and negative surface marker populations was not clear, isotype-matched control Ab staining was used to set cutoffs for phenotypic markers.


Figure 1
View larger version (49K):
[in this window]
[in a new window]

  		FIGURE 1. Flow cytometric detection of CD4+ T cell cytokine expression in whole blood incubated with BCG for 12 h from a single 10-wk-old BCG-vaccinated infant. The cutoff gates for cytokine expression were determined using unstimulated T cells from whole blood incubated with costimulants only (A). Cytokine expression in CD4+ T cells from whole blood incubated with BCG (B) and with SEB (C) is shown. IL-2/TNF-{alpha} subset gating was based on patterns of cytokine expression in SEB-stimulated whole blood. Dot plots are gated on CD3+CD4+ T cells and are representative of 29 infants.

 
Plasma cytokine detection

Plasma was collected from the stimulated whole blood after 7 h and cryopreserved. Later, thawed plasma was used to measure levels of IL-2, IL-4, IL-10, and IFN-{gamma} with multiplex beads according to the manufacturer’s instructions (Bio-Rad) and read on a luminometer (Luminex). The range of detection for all cytokines was 1.95–32,000 pg/ml. The optimal plasma dilution for our assay, determined in pilot experiments, was 1/4. Background cytokine levels measured in plasma harvested from unstimulated blood were subtracted from BCG-stimulated blood.

Statistical considerations

Negative control (background) values for cytokine expression were not subtracted from BCG-induced responses, because the median backgrounds for all CD4+ T cell subsets was 0.001% (range, 0.000–0.01%) and for CD8+ T cell subsets was 0.000% (range, 0.000–0.01%). We used an empiric cutoff value of 0.01% as positive: given that a median of 508,509 CD4+ T cells and 188,498 CD8+ T cells was collected, this cutoff was predicted to be >90% different from background, at an {alpha} of 0.05 (35). IL-4 and IL-10 expression was reported with backgrounds (see below). Nonparametric tests were used to compare differences in cytokine expression and phenotypic profiles between CD4+ and CD8+ T cells. Associations between cellular expression of cytokines and plasma levels of these were assessed by the nonparametric Spearman test. Data were considered statistically significant when p < 0.05. Statistical analysis was performed using GraphPad Prism 4 software.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
BCG-specific CD4+ and CD8+ T cell type 1 cytokine production

Intracellular expression of three type 1 cytokines thought to be critical for protective immunity against mycobacteria, IFN-{gamma}, IL-2 and TNF-{alpha} (36, 37), was evaluated by incubating blood from 29 BCG-vaccinated infants with BCG for 12 h (Fig. 1). The median frequencies of CD4+ T cells expressing either IFN-{gamma} or IL-2 or TNF-{alpha} were similar (Fig. 2A). Lower frequencies of CD8+ T cells expressed IFN-{gamma}, IL-2 (p < 0.05), or TNF-{alpha} (p < 0.0001), compared with CD4+ T cells (Fig. 2A). There was a strong positive correlation between the frequencies of IFN-{gamma}- or IL-2- or TNF-{alpha}-expressing CD4+ and CD8+ T cells (r = 0.770, r = 0.879, r = 0.760, respectively, all p < 0.0001, Spearman test).


Figure 2
View larger version (41K):
[in this window]
[in a new window]

  		FIGURE 2. Cytokine profiles of BCG-specific T cells in 10-wk-old infants vaccinated at birth. A, Frequency of CD4+ and of CD8+ T cells expressing individual type 1 cytokines following incubation of blood with BCG for 12 h in 29 infants. Responses above 0.01% were considered positive. The horizontal line indicates the median and the whiskers indicate the interquartile range. B, Frequency of BCG-specific CD4+ T cells expressing different combinations of type 1 cytokines. C, Frequency of BCG-specific CD8+ T cells expressing different combinations of type 1 cytokines. D, Representative staining of intracellular type 1 cytokines in BCG-specific CD4+ T cells and CD8+ T cells from a single 10-wk-old infant. Cutoff gates for cytokine expression were determined using unstimulated T cells from whole blood incubated with costimulants only. IL-2/TNF-{alpha} subset gating was based on patterns of cytokine expression in SEB-stimulated whole blood. E, Comparison of frequency of CD4+ and of CD8+ T cells expressing IFN-{gamma} (dark bars) with frequency of T cells expressing IL-2 and/or TNF-{alpha} without IFN-{gamma} (light bars) in 29 BCG-vaccinated infants.

 
Analysis of simultaneous expression of IFN-{gamma}, IL-2, and TNF-{alpha} on a single cell level revealed seven distinct type 1 cytokine-expressing CD4+ T cell populations (Fig. 2B). Among CD8+ T cells, the dominant population expressed IFN-{gamma} only; three other populations were discernable (Fig. 2C). Importantly, a substantial proportion of CD4+ T cells expressing IL-2 and/or TNF-{alpha} did not coexpress IFN-{gamma} (Fig. 2D). Similarly, among CD8+ T cells, a proportion of IL-2-expressing T cells also did not coexpress IFN-{gamma} (Fig. 2D). Total type 1 T cell responses were dominated by IFN-{gamma} expression; however, measuring IFN-{gamma} alone did not detect all type 1 cytokine-expressing T cells (Fig. 2E).

All three type 1 cytokines could also be detected in plasma (data not shown). There was a significant correlation between plasma levels of IFN-{gamma}, IL-2, and TNF-{alpha} and frequencies of CD4+ T cells producing these cytokines (Table I). Plasma IFN-{gamma} and IL-2 also correlated with frequencies of CD8+ T cells producing IFN-{gamma} and IL-2, respectively (Table I).


View this table:
[in this window]
[in a new window]

  		Table I. Association between type 1 cytokine levels in plasma and frequencies of CD4+ or CD8+ T cells expressing these cytokines after incubation of whole blood with BCGa

 
Taken together, we concluded that BCG vaccination of newborns induces multiple type 1 T cell subsets defined by expression of distinct cytokine combinations.

BCG-specific IL-10 and type 2 cytokine production

The frequency of T cells expressing IL-10 or IL-4 following incubation of whole blood with BCG was low (Fig. 3). Few donors had responses above 0.01%, our cutoff for a positive response, but IL-10 and IL-4 production was consistently above the background expression levels found in blood not incubated with BCG (Fig. 3, B and D). CD4+ T cell expression of both cytokines was slightly higher than that of CD8+ T cells (CD4+ T cell expression shown in Fig. 3; CD8+ T cells: median, 0.004%; range, 0.001–0.024%, expressed IL-10 and median, 0.005%; range, 0.000–0.011%, expressed IL-4). IL-10 and IL-4 were never coexpressed by cells making type 1 cytokines (Fig. 3, A and C). Intracellular IL-4 could be readily detected in HICK-2 cytokine-expressing cells, which served as positive control (Fig. 3C). IL-4 and IL-10 were detected at low levels in plasma of whole blood incubated with BCG (Fig. 4).


Figure 3
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 3. Expression of IL-10 (A) and IL-4 (C) in CD4+ T cells from whole blood from a single, vaccinated infant incubated with costimulants (UNS), BCG, or SEB. Frequency of CD4+ T cells expressing IL-10 (B) and IL-4 (D) following incubation of blood with costimulants only (light bars) and BCG (dark bars) for 12 h in 29 infants.

 

Figure 4
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 4. Levels of IL-4 and IL-10 in plasma from whole blood incubated with BCG for 7 h. The horizontal line represents the median. Background cytokine levels were subtracted.

 
We concluded that BCG vaccination of newborns induces low levels of IL-4 and IL-10 expression.

Phenotypic profiles of specific type 1 T cell subsets

Studies in other infectious disease models have shown that distinct populations of Ag-experienced T cells may be associated with long-lived protection (38). We therefore examined the phenotypic profiles of BCG-induced T cells. Specific CD4+ T cells were defined as either IFN-{gamma}- or IL-2-expressing (Fig. 5, A–D); frequencies of cells expressing other cytokines were too low to reliably delineate the phenotype. Five major and distinct Ag-experienced CD4+ T cells subsets could be discerned, based on expression of CD45RA, CCR7, and CD27 (Fig. 6, A–C). By far the most common phenotype of both IFN-{gamma}- and IL-2-expressing CD4+ T cells was CD45RA–CCR7–CD27+ (Fig. 6A), a phenotype that has been reported to be characteristic of effector T cells (13). The second most common phenotype among IFN-{gamma}-expressing CD4+ T cells was CD45RA–CCR7–CD27–, also characteristic of effector T cells (Fig. 6A). Among IL-2-expressing CD4+ T cells, the latter population was significantly less frequent (Fig. 6A), while central memory phenotypes were more common: IL-2+ cells were more likely to be CD45RA–CCR7+CD27+, CD45RA+CCR7–CD27+, or CD45RA+CCR7+CD27+, compared with IFN-{gamma}-expressing CD4+ T cells (Fig. 6A). CD4+ T cells that expressed both IFN-{gamma} and IL-2 were predominantly effector memory cells (CD45RA–CCR7–CD27+ or CD45RA– CCR7+CD27+; Fig. 6B). As a comparison, the expression of phenotypic markers among cytokine-negative CD4+ T cells are depicted in Fig. 6C.


Figure 5
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 5. Phenotype of BCG-specific CD4+ T cells in 10-wk-old infants vaccinated at birth. Ag-specific CD4+ T cells were identified by expression of intracellular IFN-{gamma} (A), IL-2 (B), or both cytokines (C), and the expression of CD45RA, CCR7, and CD27 was determined in each case. The plots illustrate the distribution of cytokine-expressing cells (in color; foreground) in relation to the entire CD4+ T cell population (gray; background, also shown in D).

 

Figure 6
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 6. Frequency of different subsets of BCG-specific CD4+ T cells, based on expression of CD45RA, CCR7, and CD27 among IFN-{gamma}+ and IL-2+ (A) and IFN-{gamma}+IL-2+ (B), expressing CD4+ T cells. C, Frequency of these cells among cytokine-negative, i.e., mostly mycobacteria-nonspecific, CD4+ T cells. D, Frequency of different subsets of BCG-specific CD8+ T cells among IFN-{gamma}+ expressing cells. E, Frequency of these cells among mycobacteria-nonspecific CD8+ T cells. The horizontal line represents the median and the whiskers the interquartile range. *, p < 0.05; ns, p ≥ 0.05.

 
Phenotypes of BCG-specific CD8+ T cells could reliably be detected only for IFN-{gamma}-producing cells, because the frequencies of IL-2-producing CD8+ T cells were too low. CD8+IFN-{gamma}+ T cells also displayed a predominant CD45RA–CCR7–CD27+ effector phenotype (Fig. 6D). Unlike CD4+IFN-{gamma}+ T cells, a central memory population (CD45RA+CCR7+CD27+) was the second most common. The expression of phenotypic markers among cytokine-negative CD8+ T cells are depicted in Fig. 6E.

We concluded that the majority of specific T cells induced by BCG vaccination of newborns has an effector phenotype and that IL-2 expression is more likely to be associated with a central memory phenotype.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
We showed that BCG vaccination of human newborns induces a diverse set of T cells, delineated by distinct cytokine production and phenotypic profiles. BCG-specific T cells produced mainly type 1 cytokines, as has been demonstrated before (14, 15, 16, 20, 22). However, we showed that not only IFN-{gamma} is produced. A considerable number of IFN-{gamma}-negative CD4+ T cells were present, expressing the other type 1 cytokines IL-2 and TNF-{alpha}. Similarly, many CD8+ T cells produced IL-2 in the absence of IFN-{gamma}. The most commonly used measure of mycobacteria-induced immunity today is IFN-{gamma} production, be this to diagnose latent infection via IFN-{gamma} release assays (39, 40) or to describe human immune responses to novel TB vaccines (41). Recent experimental data suggest that measuring IFN-{gamma} may not correlate with vaccination-induced protection against TB (42, 43, 44). This strongly supports measurement of all three cytokines on a cellular level to delineate a mycobacteria-specific type 1 response. This is further supported by our observation that diversity in the T cell cytokine response was predominant in our study population, e.g., in some infants cells that produced one cytokine dominated, whereas in others cells that produced three cytokines dominated. Measuring a single component of the immune response may underestimate the magnitude and complexity of BCG-induced immunity.

A BCG-induced CD8+ T cell response was readily detectable, as type 1 cytokine-producing cells. Murine studies suggest that CD8+ T cells play an important role in control of M. tuberculosis infection and contribute substantially to total IFN-{gamma} production (4). Although a BCG-induced CD8+ T cell response has been described before (14, 45), we now show that the response is characterized by both IFN-{gamma}-and IL-2-producing subsets. An interesting observation was that CD8+ T cells produced very little TNF-{alpha}. Smith et al. (45) detected similar frequencies of CD8+ T cells expressing TNF-{alpha} and IFN-{gamma} following incubation of PBMC with BCG for 6 days. The contrasting low frequency of TNF-{alpha} expression observed in our study could be due to differences in assays, since we measured cytokine expression 12 h after incubation of whole blood with BCG. In longer term assays such as those performed by Smith et al. (45), TNF-{alpha} production may be derived from newly differentiated effector T cells, whereas our short-term assay measures cytokine-producing potential directly ex vivo. Our results also contrast with data from HIV-infected adults, whose HIV-specific CD8+ T cells readily express TNF-{alpha} in short-term intracellular cytokine assays (46, 47), implying that BCG-specific CD8+ T cells in newborns express little TNF-{alpha}.

The memory phenotype of BCG-induced T cells has not been reported. We identified five phenotypically distinct subsets within BCG-specific type 1 T cells, based on expression of CD45RA, CCR7, and CD27. The predominant phenotype of both IFN-{gamma}- and IL-2-expressing CD4+ and CD8+ T cells was CD45RA–CCR7–CD27+. CCR7– effector cells are characteristic of persistent activation of T cells seen in chronic viral infections where Ag is not cleared (48, 49, 50). Similarly, increased numbers of effector T cells are observed in children with active TB (51). It is possible that M. bovis BCG had persisted up to 10 wk of age, the time at which blood was collected from infants, resulting in this predominant phenotype.

Distinct differences in phenotypes were observed among CD4+ IFN-{gamma}- and IL-2-expressing cells. IL-2-expressing cells were significantly more likely to have a central memory phenotype, e.g., CD45RA–CCR7+CD27+, compared with IFN-{gamma}-expressing cells. IL-2-expressing T cells induced by BCG vaccination therefore follows patterns similar to those previously described for purified human central memory populations, which are likely to express IL-2 (13). However, our results, from 10 wk after vaccination with BCG, contrast with results obtained 8 wk after vaccination with tetanus toxoid; specific IL-2-expresing central memory cells were present but in a relatively small population, whereas this population was predominant after tetanus vaccination (52). Tetanus toxoid is not a persistent Ag; we therefore hypothesize that viable M. bovis BCG persisted following vaccination, driving differentiation predominantly into IFN-{gamma}-expressing effector cells and preventing differentiation into IL-2-expressing central memory cells. An alternate hypothesis is that continuous exposure to environmental mycobacteria may contribute to chronic immune activation and therefore a predominance of effector T cells. The infants in this study were from a region with high rates of environmental mycobacteria and unpublished data suggest that exposure may occur even within the first 10 wk of life. It has been proposed that exposure to environmental mycobacterial Ags in tropical regions may undermine protective immunity induced by BCG (53). A third hypothesis is that the time point at which we measured the host response was too early for full differentiation into the central memory phenotype. A central memory/IL-2 phenotype has been associated with improved prognosis of chronic human viral infections such as HIV (49) and in experimental settings of chronic intracellular bacterial infection with long-lived protection (38). It remains to be determined whether a central memory phenotype is also associated with successful vaccination against TB.

We found that a significant amount of specific CD4+ and CD8+ T cells had a phenotype traditionally regarded as naive, i.e., CD45RA+ and CCR7+. In a recent study of children with TB, Caccamo et al. (54) also described this population, identified as specific by MHC class I pentamers of Ag-85A. We propose that this CD45RA+CCR7+ population reflects early differentiation into Ag-specific cells, before loosing CD45RA expression.

We could detect very low intracellular expression of the type 2 cytokine IL-4 above background values. Expression of type 2 cytokines has been associated with a suboptimal immune response to mycobacteria (55). For example, Ordway et al. (56) showed that long-term control of latent M. tuberculosis infection in humans appeared to be associated with optimal type 1 cytokine production and absence of detectable type 2 cytokine production. They showed that high percentages of IL-4-expressing CD8+ and {gamma}{delta} T cells soon after M. tuberculosis infection were associated with ultimate development of TB disease. The IL-4-expressing cells were detected after incubation of PBMC for 6 days, which contrasted with our 12-h assay; longer term assays may be required to detect these cells in the setting of BCG vaccination of the newborn. Intracellular expression of IL-10 could also be detected in our cohort, was low, and, like IL-4 expression, was never coexpressed with any type 1 cytokine. We propose that the IL-10-expressing T cells were induced regulatory T cells, which are expected to be present at low frequencies. Regulatory T cells control conventional effector immune responses, are induced by infections (57) and likely also by vaccination with BCG.

Our results clearly demonstrate the advantages of complex multiparameter flow cytometric analysis for deciphering a vaccination-induced immune response. However, this technology is not readily available. It is therefore important to note, from our findings, that when detection of IFN-{gamma} or IL-2 is the aim and flow cytometry is not available, plasma levels may serve as surrogates of T cell cytokine production. We showed that plasma levels of type 1 cytokines correlated strongly with intracellular expression despite the fact that non-T cells also have the ability to make these cytokines (58, 59). When only four-color flow cytometry is available, inclusion of all three type 1 cytokines in one-color channel for detecting the total type 1 response may be the most useful. This proposal is supported by observations in HIV infection, where the presence of "polyfunctional" CD8+ T cell populations, i.e., HIV-specific CD8+ T cells that coexpress multiple cytokines, was associated with better clinical outcome (46). The observation in a mouse model of Leishmania major infection that polyfunctional T cell induction is also associated with the best outcome (60) suggests that measurement of these cells may also be important following BCG vaccination, since the mechanisms of immune protection are very similar for Leishmania and mycobacteria. Regardless, measurement of all three type 1 cytokines in one color would still not delineate the complexity of cytokine expression profiles. This may be important, since other studies of HIV infection showed that IL-2 expression, rather than IFN-{gamma} or dual expression, correlated with the best clinical outcome (49). We therefore propose that delineation of multiple cytokine-expressing subsets, individually, will be important to investigate protective immunity against TB, either following natural infection or following vaccination.


   Acknowledgments
 
We acknowledge the infants who took part in this study, their families, and the support of an excellent team of researchers at our field site. We thank Dr. N. Goonetilleke and Prof. S. Gordon from the University of Oxford for initial assistance with the Luminex assay.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Aeras Global Tuberculosis Vaccine Foundation and by the European Commission, within the 6th Framework Programme (to A.H., G.D.H., and W.A.H.). T.J.S. is a Wellcome Trust Research Training Fellow (080929/Z/06/Z). G.D.H. is supported by National Institutes of Health Grant D43TW007115, G.K. by National Institutes of Health Grants RO1-AI66046, RO1-AI065653, NO1-AI70022, and RO1-HL55936, and W.A.H. by National Institutes of Health Grants RO1-AI065653 and NO1-AI70022. W.A.H. is also supported by the Bill and Melinda Gates Foundation through Grand Challenges in Global Health Grants 37772 and 37885, the Dana Foundation, and the European and Developing Countries Trials Partnership. Back

2 Address correspondence and reprint requests to Dr. Willem A. Hanekom, University of Cape Town, Health Sciences, Anzio Road, Observatory 7925, South Africa. E-mail address: willem.hanekom{at}uct.ac.za Back

3 Abbreviations used in this paper: TB, tuberculosis; BCG, bacillus Calmette-Guérin; SEB, streptococcal enterotoxin B. Back

Received for publication July 31, 2007. Accepted for publication December 12, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Colditz, G. A., C. S. Berkey, F. Mosteller, T. F. Brewer, M. E. Wilson, E. Burdick, H. V. Fineberg. 1995. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96: 29-35. [Abstract/Free Full Text]
  2. Trunz, B. B., P. Fine, C. Dye. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-1180. [Medline]
  3. Flory, C. M., R. D. Hubbard, F. M. Collins. 1992. Effects of in vivo T lymphocyte subset depletion on mycobacterial infections in mice. J. Leukocyte Biol. 51: 225-229. [Abstract]
  4. Lazarevic, V., D. Nolt, J. L. Flynn. 2005. Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses. J. Immunol. 2: 1107-1117.
  5. Flynn, J. L., M. M. Goldstein, K. J. Triebold, B. Koller, B. R. Bloom. 1992. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 89: 12013-12017. [Abstract/Free Full Text]
  6. Caruso, A. M., N. Serbina, E. Klein, K. Triebold, B. R. Bloom, J. L. Flynn. 1999. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-{gamma}, yet succumb to tuberculosis. J. Immunol. 162: 5407-5416. [Abstract/Free Full Text]
  7. Elliott, A. M., S. Hodsdon, J. Kyosiimire, M. A. Quigley, J. S. Nakiyingi, P. B. Namujju, C. Watera, N. French, C. F. Gilks, H. M. Dockrell, J. A. Whitworth. 2004. Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Trans. R. Soc. Trop. Med. Hyg. 98: 660-670. [Medline]
  8. Ottenhoff, T. H., T. De Boer, J. T. van Dissel, F. A. Verreck. 2003. Human deficiencies in type-1 cytokine receptors reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Adv. Exp. Med. Biol. 531: 279-294. [Medline]
  9. van de Vosse, E., M. A. Hoeve, T. H. Ottenhoff. 2004. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect. Dis. 12: 739-749.
  10. Saliu, O. Y., C. Sofer, D. S. Stein, S. K. Schwander, R. S. Wallis. 2006. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis. 194: 486-492. [Medline]
  11. Stenger, S.. 2005. Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann. Rheum. Dis. 64: 24-28.
  12. Bouneaud, C., Z. Garcia, P. Kourilsky, C. Pannetier. 2005. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J. Exp. Med. 201: 579-590. [Abstract/Free Full Text]
  13. Sallusto, F., D. Lenig, R. Forster, M. Lipp, A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nat. Immunol. 14: 659-660.
  14. Murray, R. A., N. Mansoor, R. Harbacheuski, J. Soler, V. Davids, A. Soares, A. Hawkridge, G. D. Hussey, H. Maecker, G. Kaplan, W. A. Hanekom. 2006. Bacillus Calmette-Guérin vaccination of human newborns induces a specific, functional CD8+ T cell response. J. Immunol. 177: 5647-5651. [Abstract/Free Full Text]
  15. Ota, M. O., J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, M. Sanneh, M. Kidd, M. J. Newport, P. Aaby, H. Whittle, P. H. Lambert, et al 2002. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168: 1919-1925. [Abstract/Free Full Text]
  16. Marchant, A., T. Goetghebuer, M. O. Ota, I. Wolfe, S. J. Ceesay, D. De Groote, T. Corrah, S. Bennett, J. Wheeler, K. Huygen, et al 1999. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J. Immunol. 163: 2249-2255. [Abstract/Free Full Text]
  17. Davids, V., W. A. Hanekom, N. Mansoor, H. Gamieldien, S. J. Gelderbloem, A. Hawkridge, G. D. Hussey, E. J. Hughes, J. Soler, R. A. Murray, et al 2006. The effect of bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J. Infect. Dis. 193: 531-536. [Medline]
  18. Ordway, D. J., M. S. Martins, L. M. Costa, M. S. Freire, M. J. Arroz, H. M. Dockrell, F. A. Ventura. 2005. Increased IL-4 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease. Acta Med. Port. 18: 27-36. [Medline]
  19. Lienhardt, C., A. Azzurri, A. Amedei, K. Fielding, J. Sillah, O. Y. Sow, B. Bah, M. Benagiano, A. Diallo, R. Manetti, et al 2002. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur. J. Immunol. 32: 1605-1613. [Medline]
  20. Hussey, G. D., M. L. Watkins, E. A. Goddard, S. Gottschalk, E. J. Hughes, K. Iloni, M. A. Kibel, S. R. Ress. 2002. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology 105: 314-324. [Medline]
  21. Boussiotis, V. A., E. Y. Tsai, E. J. Yunis, S. Thim, J. C. Delgado, C. C. Dascher, A. Berezovskaya, D. Rousset, J. M. Reynes, A. E. Goldfeld. 2000. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest. 105: 1317-1375. [Medline]
  22. Vekemans, J., A. Amedei, M. O. Ota, M. M. D’Elios, T. Goetghebuer, J. Ismaili, M. J. Newport, G. Del Prete, M. Goldman, K. P. McAdam, A. Marchant. 2001. Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-{gamma} production by CD4+ T lymphocytes. Eur. J. Immunol. 31: 1531-1535. [Medline]
  23. Sallusto, F., J. Geginat, A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763. [Medline]
  24. Kaech, S. M., J. T. Tan, E. J. Wherry, B. T. Konieczny, C. D. Surh, R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4: 1191-1198. [Medline]
  25. Song, K., R. L. Rabin, B. J. Hill, S. C. De Rosa, S. P. Perfetto, H. H. Zhang, J. F. Foley, J. S. Reiner, J. Liu, J. J. Mattapallil, et al 2005. Characterization of subsets of CD4+ memory T cells reveals early branched pathways of T cell differentiation in humans. Proc. Natl. Acad. Sci. USA 102: 7916-7921. [Abstract/Free Full Text]
  26. Fritsch, R. D., X. Shen, G. P. Sims, K. S. Hathcock, R. J. Hodes, P. E. Lipsky. 2005. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J. Immunol. 175: 6489-6497. [Abstract/Free Full Text]
  27. Huster, K. M., M. Koffler, C. Stemberger, M. Schiemann, H. Wagner, D. H. Busch. 2006. Unidirectional development of CD8+ central memory T cells into protective Listeria-specific effector memory T cells. Eur. J. Immunol. 36: 1453-1464. [Medline]
  28. Geginat, J., A. Lanzavecchia, F. Sallusto. 2003. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101: 4260-4266. [Abstract/Free Full Text]
  29. Sester, M., U. Sester, P. Clauer, G. Heine, U. Mack, T. Moll, G. W. Sybrecht, A. Lalvani, H. Kohler. 2004. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int. 65: 1826-1834. [Medline]
  30. Hughes, A. J., P. Hutchinson, T. Gooding, N. J. Freezer, S. R. Holdsworth, P. D. Johnson. 2005. Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clin. Exp. Immunol. 142: 132-139. [Medline]
  31. Tesfa, L., F. W. Koch, W. Pankow, H. D. Volk, F. Kern. 2004. Confirmation of Mycobacterium tuberculosis infection by flow cytometry after ex vivo incubation of peripheral blood T cells with an ESAT-6-derived peptide pool. Cytometry B Clin. Cytom. 60: 47-53. [Medline]
  32. Hanekom, W. A., J. Hughes, M. Mavinkurve, M. Mendillo, M. Watkins, H. Gamieldien, S. J. Gelderbloem, M. Sidibana, N. Mansoor, V. Davids, et al 2004. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J. Immunol. Methods 291: 185-195. [Medline]
  33. Maecker, H. T., T. Frey, L. E. Nomura, J. Trotter. 2004. Selecting fluorochrome conjugates for maximum sensitivity. Cytometry A 62: 169-173. [Medline]
  34. Perfetto, S. P., P. K. Chattopadhyay, M. Roederer. 2004. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4: 648-655. [Medline]
  35. Motulsky, H.. 1995. Choosing an appropriate sample size. Intuitive Biostatistics 199-200. Oxford Univ. Press, New York.
  36. Flynn, J. L.. 2004. Immunology of tuberculosis and implications in vaccine development. Tuberculosis 84: 93-101. [Medline]
  37. Kaufmann, S. H.. 2005. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26: 660-667. [Medline]
  38. Zaph, C., J. Uzonna, S. M. Beverley, P. Scott. 2004. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10: 1104-1110. [Medline]
  39. Mahomed, H., E. J. Hughes, T. Hawkridge, D. Minnies, E. Simon, F. Little, W. A. Hanekom, L. Geiter, G. D. Hussey. 2006. Comparison of mantoux skin test with three generations of a whole blood IFN-{gamma} assay for tuberculosis infection. Int. J. Tuberc. Lung Dis. 10: 310-316. [Medline]
  40. Janssens, J. P., P. Roux-Lombard, T. Perneger, M. Metzger, R. Vivien, T. Rochat. 2007. Quantitative scoring of a {gamma}-interferon assay for differentiating active from latent tuberculosis. Eur. Respir. J. 30: 722-728. [Abstract/Free Full Text]
  41. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10: 1240-1244. [Medline]
  42. Hovav, A. H., J. Mullerad, L. Davidovitch, Y. Fishman, F. Bigi, A. Cataldi, H. Bercovier. 2003. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect. Immun. 71: 3146-3154. [Abstract/Free Full Text]
  43. Majlessi, L., M. Simsova, Z. Jarvis, P. Brodin, M. J. Rojas, C. Bauche, C. Nouze, D. Ladant, S. T. Cole, P. Sebo, C. Leclerc. 2006. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect. Immun. 74: 2128-2137. [Abstract/Free Full Text]
  44. Hope, J. C., M. L. Thom, B. Villarreal-Ramos, H. M. Vordermeier, R. G. Hewinson, C. J. Howard. 2005. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis. Clin. Exp. Immunol. 139: 48-56. [Medline]
  45. Smith, S. M., A. S. Malin, P. T. Lukey, S. E. Atkinson, J. Content, K. Huygen, H. M. Dockrell. 1999. Characterization of human Mycobacterium bovis bacille Calmette-Guérin-reactive CD8+ T cells. Infect. Immun. 67: 5223-5230. [Abstract/Free Full Text]
  46. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. [Abstract/Free Full Text]
  47. de Castro Cunha, R.M., E. G. Kallas, D. S. Rodrigues, M. Nascimento Burattini, R. Salomao. 2005. Interferon-{gamma} and tumour necrosis factor-{alpha} production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis. Clin. Exp. Immunol. 140: 491-497. [Medline]
  48. Baars, P. A., S. Sierro, R. Arens, K. Tesselaar, B. Hooibrink, P. Klenerman, R. A. van Lier. 2005. Properties of murine (CD8+)CD27– T cells. Eur. J. Immunol. 35: 3131-3141. [Medline]
  49. Harari, A., S. Petitpierre, F. Vallelian, G. Pantaleo. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103: 966-972. [Abstract/Free Full Text]
  50. Harari, A., F. Vallelian, G. Pantaleo. 2004. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur. J. Immunol. 34: 3525-3533. [Medline]
  51. Jacobsen, M., A. K. Detjen, H. Mueller, A. Gutschmidt, S. Leitner, U. Wahn, K. Magdorf, S. H. E. Kaufmann. 2007. Clonal expansion of CD8+ effector T cells in childhood tuberculosis. J. Immunol. 179: 1331-1339. [Abstract/Free Full Text]
  52. Harari, A., F. Vallelian, P. R. Meylan, G. Pantaleo. 2005. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol. 174: 1037-1045. [Abstract/Free Full Text]
  53. Andersen, P., T. M. Doherty. 2005. The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3: 656-662. [Medline]
  54. Caccamo, N., S. Meraviglia, C. La Mendola, G. Guggino, F. Dieli, A. Salerno. 2006. Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J. Immunol. 177: 1780-1785. [Abstract/Free Full Text]
  55. Hernandez-Pando, R., H. Orozcoe, A. Sampieri, L. Pavon, C. Velasquillo, J. Larriva-Sahd, J. M. Alcocer, M. V. Madrid. 1996. Correlation between the kinetics of Th1, Th2 cells, and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 89: 26-33. [Medline]
  56. Ordway, D. J., L. Costa, M. Martins, H. Silveira, L. Amaral, M. J. Arroz, F. A. Ventura, H. M. Dockrell. 2004. Increased Interleukin-4 production by CD8 and {gamma}{delta} T cells in health-care workers is associated with the subsequent development of active tuberculosis. J. Infect. Dis. 190: 756-766. [Medline]
  57. Grazia Roncarolo, M., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212: 28-50. [Medline]
  58. Esin, S., G. Bastoni, M. Pardini, F. Favilli, D. Bottai, G. Maisetta, W. Florio, R. Vanacore, H. Wigzell, M. Campa. 2004. Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guérin. Immunology 112: 143-152. [Medline]
  59. Feinberg, J., C. Fieschi, R. Doffinger, M. Feinberg, T. Leclerc, S. Boisson-Dupuis, C. Picard, J. Bustamante, A. Chapgier, O. Filipe-Santos, et al 2004. Bacillus Calmette-Guérin triggers the IL-12/IFN-{gamma} axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur. J. Immunol. 34: 3276-3284. [Medline]
  60. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850. [Medline]



This article has been cited by other articles:


Home page
 CVIHome page
M. Parra, A. L. Yang, J. Lim, K. Kolibab, S. Derrick, N. Cadieux, L. P. Perera, W. R. Jacobs, M. Brennan, and S. L. Morris
Development of a Murine Mycobacterial Growth Inhibition Assay for Evaluating Vaccines against Mycobacterium tuberculosis
Clin. Vaccine Immunol., July 1, 2009; 16(7): 1025 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
J. Lim, S. C. Derrick, K. Kolibab, A. L. Yang, S. Porcelli, W. R. Jacobs, and S. L. Morris
Early Pulmonary Cytokine and Chemokine Responses in Mice Immunized with Three Different Vaccines against Mycobacterium tuberculosis Determined by PCR Array
Clin. Vaccine Immunol., January 1, 2009; 16(1): 122 - 126.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soares, A. P.
Right arrow Articles by Hanekom, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soares, A. P.
Right arrow Articles by Hanekom, W. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS